

Press Release – Basel, Switzerland September 12th 2006

Genedata Collaboration Yields New Hit to Lead Solution

Enterprise screening analysis provider Genedata announces the release of a powerful new analysis module for identifying lead compounds from high throughput screening results. The module was developed alongside screening experts at international pharmaceutical company Altana Pharma and enables visualization, annotation and detailed compound filtering on biological and chemical parameters.

New release Hit Profiler exploits semantic integration technologies to display screening results and a diverse range of compound information in a compound-centric, interactive table environment. Semantic integration ensures that multiple concentration data is displayed as dose response curves, that SMILES information is rendered as chemical structures, and so on.

Dr. Werner Stuermer, Head of HTS, Altana Pharma, worked closely with Genedata's Screener team during development of the module. Altana sought to filter lists of active and selective hits on the basis of biological and chemical considerations, including ADME/Tox information corresponding to chemical classes. According to Dr. Stuermer, "lead selection has moved beyond simple activity and selectivity considerations and has become a truly multidimensional exercise".

A brief look at this year's Society for Biomolecular Sciences conference program confirms the widened scope and sheer number of parameters used in lead selection. Hit Profiler adheres to industry standards and can thus capture all kinds of discovery-relevant information. Stuermer added, "Bringing together all that information is a significant bioinformatics challenge".

"We developed Hit Profiler to satisfy a need for concise hit and lead assessment", explained Dr. Stephan Heyse, Head of Genedata Screener. Genedata has a successful and long-standing collaboration with Dr. Stuermer's team at Altana Pharma. Dr. Heyse added, "The collaboration reflects Altana's strong commitment to innovation-driven drug discovery".

Announcement: Genedata's Dr. Stephan Heyse will present at next week's Society for Biomolecular Sciences 12th annual meeting in Seattle, Washington, USA.

Contact

Genedata AG
Dr. Tobe Freeman
Head, Public Relations
Phone +41 61 697 8510
Fax +41 61 697 7244
tobe.freeman@genedata.com
www.genedata.com

Genedata specializes in discovery informatics for biotech, pharmaceuticals and the life sciences. The Company offers expertise in research informatics combined with open and scalable computational solutions. Our solutions include Genedata Phylosopher® for integrating, structuring, and analyzing research data. Genedata Screener® for high throughput screening analysis. And Genedata Expressionist® for omics data integration, processing and analysis. Founded in 1997 as a privately held spin off from Novartis, Genedata is headquartered in Basel, Switzerland and has branches in Munich (Germany), Boston (USA) and San Francisco (USA). The Company is also represented in Japan, Taiwan and Singapore. For more information about Genedata, please visit: www.genedata.com.

ALTANA Pharma AG is the pharmaceutical division of ALTANA AG (NYSE: AAA, FSE: ALT), headquartered in Konstanz, Germany. ALTANA Pharma is an internationally successful, research-based company group providing innovative pharmaceuticals that create a higher quality of life for patients, modern jobs for highly qualified employees and a good return for shareholders.

The product range of ALTANA Pharma focuses on therapeutics for the treatment of gastrointestinal and respiratory diseases, which the company develops with intense research commitment.

Further information is available on the Internet at www.altanapharma.com.

Disclaimer

The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.